Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD).
Objective:
To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).
Methods:
Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.
Results:
Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.
Conclusion:
Adding MCO to AD patients’ pharmacotherapy is safe and a promising treatment option.
Ben AmarM (2006) Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol105, 2–25.
2.
GrotenhermenG, Muller-VahlK (2012) The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int109, 495–501.
3.
WaltherS, HalpernM (2010) Cannabinoids and dementia: A review of clinical and preclinical data. Pharmaceuticals3, 2689–2708.
4.
KrishnanS, CairnsR, HowardR (2009) Cannabinoids for the treatment of dementia (Review). . Cochrane Database Syst Rev,CD007204.
5.
EubanksLM, RogersCJ, BeuscherAE4th, KoobGF, OlsonAJ, DickersonTJ, JandaKD (2006) A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm3, 773–777.
6.
RamirezBG, BlazquezC, Gomez del PulgarT, GuzmanM, de CeballosM (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci25, 1904–1913.
7.
BonnetAE, MarchalantY (2015) Potential therapeutical contributions of the endocannabinoid system towards aging and Alzheimer’s disease. Aging Dis6, 400–405.
8.
CaoC, LiY, LiuH, BaiG, MayIJ, LinX (2014) The potential therapeutic effects of THC on Alzheimer’s disease. J Alzheimers Dis42, 973–984.
9.
VolicerL, StellyM, MorrisJ, McLaughlinJ, VolicerBJ (1997) Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer’s disease. Int J Geriatr Psychiatry12, 913–919.
10.
WaltherS, MahlbergR, EichmannU, KunzD (2006) Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology185, 524–528.
11.
van den ElsenGA, AhmedAI, VerkesRJ, KramersC, FeuthT, RosenbergPB, van der MarckMA, Olde RikkertGM (2015) Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology84, 2338–2346.
12.
BostwickJM (2012) Blurred boundaries: The therapeutics and politics of medical marijuana. Mayo Clin Proc87, 172–186.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory Comprehensive assessment of psychopathology in dementia. Neurology44, 2308.
15.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
16.
GuyW (1976) ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, MD, US Department of Health, Education, and Welfare, pp. 217–222.
17.
BellardC, CreeseB, CorbettA, AarslandD (2011) Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf10, 35–43.
